Title: Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Author:Wang G, Zhang M, Meng P, Long C, Luo X, Yang X, Wang Y, Zhang Z, Mwangi J, Kamau PM, Dai Z, Ke Z, Zhang Y, Chen W, Zhao X, Ge F, Lv Q, Rong M, Li D, Jin Y, Sheng X, Lai R.

Publication Name: Acta Pharm Sin B

Pub Year: 2022

Doi: 10.1016/j.apsb.2021.12.024

IF: 14.903

Abstract: Unlike healthy, non-transformed cells, the proteostasis network of cancer cells is taxed to produce proteins involved in tumor development. Cancer cells have a higher dependency on molecular chaperones to maintain proteostasis. The chaperonin T-complex protein ring complex (TRiC) contains eight paralogous subunits (CCT1-8), and assists the folding of as many as 10% of cytosolic proteome. TRiC is essential for the progression of some cancers, but the roles of TRiC subunits in osteosarcoma remain to be explored. Here, we show that CCT4/TRiC is significantly correlated in human osteosarcoma, and plays a critical role in osteosarcoma cell survival. We identify a compound anticarin-beta that can specifically bind to and inhibit CCT4. Anticarin-beta shows higher selectivity in cancer cells than in normal cells. Mechanistically, anticarin-beta potently impedes CCT4-mediated STAT3 maturation. Anticarin-beta displays remarkable antitumor efficacy in orthotopic and patient-derived xenograft models of osteosarcoma. Collectively, our data uncover a key role of CCT4 in osteosarcoma, and propose a promising treatment strategy for osteosarcoma by disrupting CCT4 and proteostasis.